Hørsholm, Denmark (PRWEB) January 03, 2013
Visiopharm a leader of Quantitative Digital Pathology solutions announced today that Dr. Henrik Stender will join Visiopharm’s Board of Directors.
Dr. Henrik Stender is co-founder of AdvanDx, where he was the Vice President of Research & Development. While with AdvanDx, he spearheaded the development of their PNA FISH technology; including clinical and regulatory activities for in-vitro diagnostic (IVD) use in Europe and in the United States. Today, as owner of Stender Diagnostics, Dr. Stender uses an ’IVD Factory’ concept to streamline the development process towards high quality products in compliance with quality system requirements (QSR) for regulatory approvals. Prior to AdvanDx, Henrik was at Applied Biosystems, Boston Probes, and Dako, where he built a deep and broad knowledge about medical devices and in-vitro diagnostics.
“I am very excited about joining Visiopharm, and see tremendous potential for their diagnostic solutions. Visiopharm already has a strong portfolio of algorithms for nuclear, membrane, and gene-probe analysis, which is currently under clinical validation and subsequent deployment at several hospitals. Still, there is a strong focus on developing and validating novel technology in software modules that truly addresses the demand for doing things better, faster, and cheaper. I believe this will be part of defining the future of Digital Pathology”, says Dr. Henrik Stender.
Michael Grunkin, CEO at Visiopharm stated “In-vitro diagnostics is a key business area for Visiopharm. We have an exciting development pipeline of IVD algorithms for the breast tumor panel, and this will set the foundation for the development of several other tumor panels. Dr. Stender is an important addition to our Board of Directors. His extensive knowledge and experience in the development of IVD products will be a great contribution to Visiopharm."
Johan Doré, CTO at Visiopharm adds, “We are seeing some interesting changes in Scandinavia these years, when it comes to adoption of Digital Pathology. We are collaborating with several hospitals in moving Digital Pathology into the clinic, and we have a very strong clinical network for validation though our close collaboration with the NordiQC. With his experience, Henrik is helping us optimizing our development work and clinical network in a regulatory context.”
Visiopharm recently introduced the HER2-CONNECT algorithm as their first CE-IVD cleared module and they are scheduled to launch a full CE-IVD tumor panel in 2013.
Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 350 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.